Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Mar
20
Today In Oncology
AMA Survey Finds Rapid Growth in Physician AI Adoption
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
High Cancer Burden Shifted From Urban to Rural Areas
Study Finds No Overall Increase in Cancer Risk After Medically Assisted Reproduction
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo